Showing results (81-90 of 410) with videos related to
Sort By:
Pageof 41
Cancer Immunology Research|May 7, 2015
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic MelanomaJason J Luke, Hilary Donahue, Mizuki Nishino, et al.Dermatology Online Journal|July 5, 2020
Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexateAakaash Varma, Philip Friedlander, Ellen H De Moll, et al.Oncoimmunology|June 15, 2018
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanomaXinqi Wu, Anita Giobbie-Hurder, Erin M Connolly, et al.JAMA Oncology|October 4, 2017
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysisRomualdo Barroso-Sousa, William T Barry, Ana C Garrido-Castro, et al.Clinical and Translational Gastroenterology|April 7, 2026
Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and ComplicationsMatthew J Townsend, Afeerah Mumtaz, Jordan S Sack, et al.Immunotherapy|June 13, 2022
Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profilingKevin Tyan, Osama Abu-Shawer, Joanna Baginska, et al.Cancer Treatment Reviews|July 26, 2014
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanomaDavid McDermott, Celeste Lebbé, F Stephen Hodi, et al.Hepatology (Baltimore, Md.)|October 28, 2021
Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitisMichael Li, Danny Wong, Alexander S Vogel, et al.Journal of the National Cancer Institute|August 29, 2012
When progressive disease does not mean treatment failure: reconsidering the criteria for progressionGeoffrey R Oxnard, Michael J Morris, F Stephen Hodi, et al.Anticancer Research|March 28, 2023
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in MelanomaPhilip Friedlander, Lee Roy Morgan, Edmund N Benes, et al.Pageof 41